Effect of Personalized Risk-Reduction Strategies on Cognition and Dementia Risk Profile Among Older Adults

Abstract

ImportanceModifiable risk factors are hypothesized to account for 30% to 40% of dementia; yet, few trials have demonstrated that risk-reduction interventions, especially multidomain, are efficacious.ObjectiveTo determine if a personalized, multidomain risk reduction intervention improves cognition and dementia risk profile among older adults.Design, Setting, and ParticipantsThe Systematic Multi-Domain Alzheimer Risk Reduction Trial was a randomized clinical trial with a 2-year personalized, risk-reduction intervention. A total of 172 adults at elevated risk for dementia (age 70-89 years and with ≥2 of 8 targeted risk factors) were recruited from primary care clinics associated with Kaiser Permanente Washington. Data were collected from August 2018 to August 2022 and analyzed from October 2022 to September 2023.InterventionParticipants were randomly assigned to the intervention (personalized risk-reduction goals with health coaching and nurse visits) or to a health education control.Main Outcomes and MeasuresThe primary outcome was change in a composite modified Neuropsychological Test Battery; preplanned secondary outcomes were change in risk factors and quality of life (QOL). Outcomes were assessed at baseline and 6, 12, 18, and 24 months. Linear mixed models were used to compare, by intention to treat, average treatment effects (ATEs) from baseline over follow-up. The intervention and outcomes were initially in person but then, due to onset of the COVID-19 pandemic, were remote.ResultsThe 172 total participants had a mean (SD) age of 75.7 (4.8) years, and 108 (62.8%) were women. After 2 years, compared with the 90 participants in the control group, the 82 participants assigned to intervention demonstrated larger improvements in the composite cognitive score (ATE of SD, 0.14; 95% CI, 0.03-0.25; P = .02; a 74% improvement compared with the change in the control group), better composite risk factor score (ATE of SD, 0.11; 95% CI, 0.01-0.20; P = .03), and improved QOL (ATE, 0.81 points; 95% CI, −0.21 to 1.84; P = .12). There were no between-group differences in serious adverse events (24 in the intervention group and 23 in the control group; P = .59), but the intervention group had greater treatment-related adverse events such as musculoskeletal pain (14 in the intervention group vs 0 in the control group; P < .001).Conclusions and RelevanceIn this randomized clinical trial, a 2-year, personalized, multidomain intervention led to modest improvements in cognition, dementia risk factors, and QOL. Modifiable risk-reduction strategies should be considered for older adults at risk for dementia.Trial RegistrationClinicalTrials.gov Identifier: NCT03683394

Japan‐Multimodal Intervention Trial for the Prevention of Dementia: A randomized controlled trial

“…Nonetheless, a recent study involving 172 older adults aged 70 to 89 years, each with at least two dementia risk factors targeted by the intervention, revealed that a 2‐year, personalized, multidomain intervention resulted in enhanced cognitive function. 28 This result implies that initiating interventions is not too late and highlights the potential importance of personalized or tailored interventions among older adults in the late stages of life.…”

Association of a pace of aging epigenetic clock with rate of cognitive decline in the Framingham Heart Study Offspring Cohort

“…Ultimately, tools like DunedinPACE could prove useful to clinicians treating cognitively intact older adults with subjective complaints, uncertain ADRD biomarker classifications, and ambiguous trajectories of cognitive decline. In the near term, DunedinPACE and related tools could enhance risk stratification for intervention studies 49 . Finally, the connections between pace of aging and cognitive decline identified in our results suggests that interventions that slow pace of aging may also contribute to neuroprotection.…”

Age-associated dementia among older people aging with HIV in the United States: a modeling study

“…Improving engagement in care would reduce competing HIVrelated mortality, which could, however, further increase the lifetime risk of developing AAD, unless interventions to reduce AAD risk are made available and accessible. Interventions to counter disadvantageous social determinants of health, reduce tobacco use, and treat substance use disorder are, therefore, essential to improve life expectancy and reduce the lifetime risk of AAD among people aging with HIV, such as has been investigated in the general population [60]. A published cost-effectiveness analysis showed that interventions aimed at lowering vascular risk factors, such as treating hypertension and smoking cessation, could be cost-effective in reducing dementia among the general population [61].…”